Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health.

Ertl, Hildegund C J; Currie, Sue L; Luber, Andrew D

Ertl, Hildegund C J; Currie, Sue L; Luber, Andrew D.

Ertl HCJ; The Wistar Institute, Philadelphia, PA, United States.
Currie SL; Virion Therapeutics, LLC, Newark, DE, United States.
Luber AD; Virion Therapeutics, LLC, Newark, DE, United States.

Front Immunol ; 13: 985382, 2022.

Article in English | MEDLINE | ID: covidwho-2022757

Subject(s)

Adenovirus Vaccines; COVID-19; Vaccines; Adenoviridae/genetics; COVID-19/prevention & control; COVID-19 Vaccines; Global Health; Humans

Keywords

COVID; VITT; adenoviral (Ad) vector; benefit-risk strategies; global public health; myocarditis; thrombosis with thrombocytopenia syndrome (TTS); vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / Adenovirus Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.985382

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google